Eli Lilly and Company's one-team mindset aims to templatize facility design while remaining nimble enough to react to new manufacturing breakthroughs.
- Field Notes: APEC RHSC's Workshop On ATMP Development And Evaluation
- U.S. Pharma Tariffs And MFN Become Law After April 2 Update
- How To Implement Post-Approval Changes On A Global Level
- March 2026 — CDMO Opportunities And Threats Report
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
- Mastering Biotech's Insourcing/Outsourcing Trade-Offs
- From Principles To Practice: Building Quality Into Generative AI-Assisted Pharma Operations
- Mitigating Challenges In Solid Tumor Delivery
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Predicting Antibody-Dependent Cell-Mediated Cytotoxicity
We developed and validated a dual screening procedure (genotype and phenotype) for Lonza human peripheral blood mononuclear cells (PBMCs) to identify donors with high ADCC potential.
-
Automated NGS Solutions Advance Rare Disease Research
See how a unified NGS workflow is helping a major pediatric genetics lab boost efficiency, manage growing sample volumes, and accelerate insights into rare diseases through streamlined automation.
-
Innovating The mAb Characterization Process
Understanding the characteristics of a molecule's "personality" is crucial for optimizing development and manufacturing. Learn how to overcome the challenges in the characterization process.
-
FDA's Regenerative Medicine Advanced Therapy (RMAT) Program
RMAT qualification requires preliminary clinical evidence demonstrating the potential to address an unmet medical need. This designation grants benefits like intensive guidance and faster FDA review.
-
Tailored Approach Supports Bladder Cancer Breakthrough
Discover how a flexible operational strategy and expert site management help bladder cancer programs overcome complex logistical hurdles and achieve critical regulatory milestones.
-
Expansion Of Human Bone Marrow-Derived MSCs
Achieving over 870 million viable, quality mesenchymal stem/stromal cells is possible. This efficient cell culture method scales bone marrow-derived MSCs for clinical needs.
-
Performance Of A Customizable DMSO-Free Cryopreservation Media Formulation
Cryopreservation enables cell therapy by storing cells long-term. A DMSO-free formula preserves cell viability and health, minimizing toxicities linked with traditional cryoprotectants.
-
Boosting CMC Regulatory Efficiency In Gene Therapy
Ensure your business stays ahead in today’s complex regulatory environment by implementing robust regulatory affairs strategies that streamline compliance and product approvals.
-
Supporting Complex Manufacturing For Liquid And Lyophilized Drug Products
Aseptic fill and finish operations gain efficiency and precision with modular isolator technology, inline weight checks, and lyophilization, which are ideal for mRNA-LNPs and other sensitive modalities.
-
Streamline Analytical Tech Transfer Through Analytical Target Profile
Analytics debt in CGT can derail timelines and budgets. Learn how early ATP planning and cross-functional alignment can eliminate costly setbacks and accelerate IND approvals.
NEWSLETTER ARCHIVE
- 04.17.26 -- Large Molecule Capacity Powering Cell & Gene Therapies
- 04.17.26 -- Building Smarter Cell Therapies With AI And Synthetic Biology
- 04.16.26 -- Cell & Gene Capabilities That You Need to Know
- 04.16.26 -- Prioritizing Quality, Fit, And Supplier Reliability In CGT Materials
- 04.15.26 -- Faster, More Efficient Cell & Gene Therapy Workflows with ddPCR
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections